Seeking to explore an additional combination agent, abemaciclib was selected as it is an approved CDK4/6 inhibitor, and chordomas have a near universal loss of CDKN2A and p16 resulting in activation of CDK4/6. This evidence concerns the gene CDKN2A and chordoma.